CSCO2021 Professor Li Jin: New Hope for HER2 Positive Solid Tumors New ADC Drug MRG002 Phase I Study Announced

On September 25-29, 2021, the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting will be held as scheduled to promote the continuous development of China's oncology field

On September 25, 2021, in the main venue on the first day of the CSCO Academic Annual Conference, Professor Li Jin, the chairman of the CSCO Conference, Dongji University Affiliated Oriental Hospital (Shanghai Oriental Hospital), issued the title "Evaluation of Recombinant Humanized Anti-HER2 Monoclonal Antibody for Injection" -MMAE conjugate (MRG002) in patients with HER2-positive advanced solid tumors, the safety, tolerability, dose escalation and expansion of clinical research" important report, for the development of anti-HER2 ADC drugs in China painted a strong color One stroke

On behalf of the clinical trial team, Professor Li Jin expressed his gratitude to the conference for selecting this study as the keynote venue report, and then reviewed the background of the rapid development of ADC drugs in recent years, which are gradually becoming a new choice for the treatment of HER2-positive solid tumors

MRG002 is an emerging ADC drug independently developed in China.

On the basis of fully analyzing the structure and mechanism of MRG002, Professor Li Jin announced the progress of the phase I clinical study of MRG002 applied to HER2-positive advanced solid tumors.

25 patients in the phase Ⅰa dose escalation stage received 0.

In the safety results, Professor Li Jin pointed out that common adverse events are cytotoxic drug-related leukopenia and liver function effects, and the overall safety is tolerable

The 51 patients enrolled in the phase Ib dose expansion phase were studied at 2.

Professor Li Jin further analyzed the effect of MRG002 on HER2-positive breast cancer and gastric cancer in the entire phase I study

Regarding the safety of the Phase Ib study, the common adverse reactions were decreased neutrophil count (46%), increased LDH (43%), mostly grade 1 to 2; common (incidence rate ≥10%) grade 3 The only adverse reaction was a decrease in neutrophil count (17%), and there were no life-threatening adverse events

The preliminary results of the study have been announced at this year’s ESMO meeting.

After Professor Li Jin's explanation, under the auspices of Professor Guo Jun from Peking University Cancer Hospital, Professor Liang Jun and Professor Li Jin from Peking University International Hospital discussed the safety and drug resistance of ADC drugs

At the end of this session, Professor Li Jin called on oncologists across the country to work together to speed up the process of follow-up trials, especially in the field of gastric cancer and breast cancer, to help MRG002 go on the market as soon as possible, and bring more choices and more benefits to patients